Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | CCND1 | P24385 | 3/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 2/20 | 0.33 |
| ▸ | PRKACG | P22612 | 2/20 | 0.33 |
| ▸ | PRKACB | P22694 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783120 | 0.86 | AADAT (0.30) | — | |
| SCHEMBL2819610 | 0.86 | AADAT (0.30) | — | |
| SCHEMBL3617948 | 0.79 | MTOR (0.32) | MAP3K5HDAC1HDAC8HDAC6 | |
| SCHEMBL3605732 | 0.79 | KCNH2 (0.31) | — | |
| SCHEMBL3607054 | 0.79 | KDM1A (0.32) | — | |
| SCHEMBL3791778 | 0.74 | BPTF (0.33) | — | |
| SCHEMBL3778688 | 0.74 | BPTF (0.33) | — | |
| SCHEMBL3606058 | 0.74 | CNR1 (0.35) | — | |
| SCHEMBL2822335 | 0.70 | KCNH2 (0.30) | — | |
| SCHEMBL4212847 | 0.69 | KDM1A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | CDK4 344/4885CCND1 441/4885CCNE2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.